Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis.

Lindsay R, Miller P, Pohl G, Glass EV, Chen P, Krege JH

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA16 Oct 2008Cited by 49 (Europe PMC)

PMID18923884DOI10.1007/s00198-008-0766-0PepBankPUB-18923884

Publisher page PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In osteoporotic women, clinical vertebral fractures occurred primarily in the first interval in teriparatide groups, whereas placebo fractures appeared to increase over time.
In plain wordsIn women with osteoporosis, vertebral fractures occurred mainly early with teriparatide, whereas placebo fractures appeared to increase over time.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableTiming of clinical vertebral fractures
Study
n = 1,637
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
Clinical vertebral fractures appeared to increase over time in the placebo group and occurred primarily in the first time interval in the teriparatide treatment groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Postmenopausal women with osteoporosis were randomized to once-daily subcutaneous injection with placebo (N = 544), teriparatide 20 microg (TPTD20; N = 541), or teriparatide 40 microg (TPTD40; N = 552) plus calcium and vitamin D supplementation.
Summary · context
The time to first nonvertebral fragility fracture and new or worsening back pain following treatment initiation was analyzed using Cox partial likelihood regression treating time on therapy as a linear, time-dependent covariate.
Report a problemFND-1892388403
02HumanRandomized controlled trialEfficacy outcome
In osteoporotic women, nonvertebral fragility fracture hazard relative to placebo decreased by 7.6% per additional month of teriparatide treatment.
In plain wordsIn women with osteoporosis, fracture hazard relative to placebo decreased with each additional month of higher-dose teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseNonvertebral fragility fracture hazard, TPTD40
Study
n = 1,096
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg daily · subcutaneousAs given in this study (human).
Measurements
Decrease in relative hazard of nonvertebral fragility fractures per additional month
7.6%
TPTD40 versus placebo
Hazard ratio for nonvertebral fragility fractures per additional month
0.924 hazard ratio
TPTD40 versus placebo
95% CI of hazard ratio for nonvertebral fragility fractures
0.871 to 0.981 hazard ratio
TPTD40 versus placebo
Source sentences
Summary
Compared with placebo, the relative hazard for nonvertebral fragility fractures decreased by 7.3% for each additional month of TPTD20 [hazard ratio = 0.927, 95% CI (0.876 to 0.982), p = 0.009] and by 7.6% for each additional month of TPTD40 [hazard ratio = 0.924, 95% CI (0.871 to 0.981), p = 0.009].
2 context sentences(design, population, supporting numbers)
Summary · context
Postmenopausal women with osteoporosis were randomized to once-daily subcutaneous injection with placebo (N = 544), teriparatide 20 microg (TPTD20; N = 541), or teriparatide 40 microg (TPTD40; N = 552) plus calcium and vitamin D supplementation.
Summary · context
The time to first nonvertebral fragility fracture and new or worsening back pain following treatment initiation was analyzed using Cox partial likelihood regression treating time on therapy as a linear, time-dependent covariate.
Report a problemFND-1892388402
03HumanRandomized controlled trialEfficacy outcome
In osteoporotic women, back pain hazard relative to placebo decreased by 8.7% per additional month of teriparatide treatment.
In plain wordsIn women with osteoporosis, back pain hazard relative to placebo decreased with each additional month of higher-dose teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseBack pain hazard, TPTD40
Study
n = 1,096
Comparator
Placebo
Outcome group
Pain · Musculoskeletal
Studied dose
40 microg daily · subcutaneousAs given in this study (human).
Measurements
Decrease in relative hazard of back pain per additional month
8.7%
TPTD40 versus placebo
Hazard ratio for back pain per additional month
0.917 hazard ratio
TPTD40 versus placebo
95% CI of hazard ratio for back pain
0.898 to 0.935 hazard ratio
TPTD40 versus placebo
Source sentences
Summary
Compared with placebo, the relative hazard of back pain was decreased by 8.3% for each additional month of TPTD20 [hazard ratio = 0.920, 95% CI (0.902 to 0.939), p < 0.001] and 8.7% for each additional month of TPTD40 [hazard ratio = 0.917, 95% CI (0.898 to 0.935), p < 0.001].
2 context sentences(design, population, supporting numbers)
Summary · context
Postmenopausal women with osteoporosis were randomized to once-daily subcutaneous injection with placebo (N = 544), teriparatide 20 microg (TPTD20; N = 541), or teriparatide 40 microg (TPTD40; N = 552) plus calcium and vitamin D supplementation.
Summary · context
The time to first nonvertebral fragility fracture and new or worsening back pain following treatment initiation was analyzed using Cox partial likelihood regression treating time on therapy as a linear, time-dependent covariate.
Report a problemFND-1892388405
04HumanRandomized controlled trialEfficacy outcome
In osteoporotic women, nonvertebral fragility fracture hazard relative to placebo decreased by 7.3% per additional month of teriparatide treatment.
In plain wordsIn women with osteoporosis, fracture hazard relative to placebo decreased with each additional month of lower-dose teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseNonvertebral fragility fracture hazard, TPTD20
Study
n = 1,085
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg daily · subcutaneousAs given in this study (human).
Measurements
Decrease in relative hazard of nonvertebral fragility fractures per additional month
7.3%
TPTD20 versus placebo
Hazard ratio for nonvertebral fragility fractures per additional month
0.927 hazard ratio
TPTD20 versus placebo
95% CI of hazard ratio for nonvertebral fragility fractures
0.876 to 0.982 hazard ratio
TPTD20 versus placebo
Source sentences
Summary
Compared with placebo, the relative hazard for nonvertebral fragility fractures decreased by 7.3% for each additional month of TPTD20 [hazard ratio = 0.927, 95% CI (0.876 to 0.982), p = 0.009] and by 7.6% for each additional month of TPTD40 [hazard ratio = 0.924, 95% CI (0.871 to 0.981), p = 0.009].
2 context sentences(design, population, supporting numbers)
Summary · context
Postmenopausal women with osteoporosis were randomized to once-daily subcutaneous injection with placebo (N = 544), teriparatide 20 microg (TPTD20; N = 541), or teriparatide 40 microg (TPTD40; N = 552) plus calcium and vitamin D supplementation.
Summary · context
The time to first nonvertebral fragility fracture and new or worsening back pain following treatment initiation was analyzed using Cox partial likelihood regression treating time on therapy as a linear, time-dependent covariate.
Report a problemFND-1892388401
05HumanRandomized controlled trialEfficacy outcome
In osteoporotic women, back pain hazard relative to placebo decreased by 8.3% per additional month of teriparatide treatment.
In plain wordsIn women with osteoporosis, back pain hazard relative to placebo decreased with each additional month of lower-dose teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseBack pain hazard, TPTD20
Study
n = 1,085
Comparator
Placebo
Outcome group
Pain · Musculoskeletal
Studied dose
20 microg daily · subcutaneousAs given in this study (human).
Measurements
Decrease in relative hazard of back pain per additional month
8.3%
TPTD20 versus placebo
Hazard ratio for back pain per additional month
0.92 hazard ratio
TPTD20 versus placebo
95% CI of hazard ratio for back pain
0.902 to 0.939 hazard ratio
TPTD20 versus placebo
Source sentences
Summary
Compared with placebo, the relative hazard of back pain was decreased by 8.3% for each additional month of TPTD20 [hazard ratio = 0.920, 95% CI (0.902 to 0.939), p < 0.001] and 8.7% for each additional month of TPTD40 [hazard ratio = 0.917, 95% CI (0.898 to 0.935), p < 0.001].
2 context sentences(design, population, supporting numbers)
Summary · context
Postmenopausal women with osteoporosis were randomized to once-daily subcutaneous injection with placebo (N = 544), teriparatide 20 microg (TPTD20; N = 541), or teriparatide 40 microg (TPTD40; N = 552) plus calcium and vitamin D supplementation.
Summary · context
The time to first nonvertebral fragility fracture and new or worsening back pain following treatment initiation was analyzed using Cox partial likelihood regression treating time on therapy as a linear, time-dependent covariate.
Report a problemFND-1892388404

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.